Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

An Open-label, Phase II Study of KPS-0373 in Patients With SCD

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00863538

Enrollment

Registered

2009-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2010-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinocerebellar Degeneration

Keywords

Spinocerebellar degeneration, Thyrotropin-Releasing Hormone (TRH), SCD

Brief summary

To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD

Interventions

DRUGKPS-0373

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* SCD with mild to moderate ataxia

Exclusion criteria

* Patients with secondary ataxia * Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Design outcomes

Primary

Measure	Time frame
Scale for the assessment and rating of ataxia (SARA), ADL(Flow-FIM), Patient Improvement Impression	12 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026